Repros Therapeutics Inc.' Proellex®-V Shows Consistent Efficacy in Uterine Fibroids Phase 2 Study
THE WOODLANDS, Texas, July 23, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it will complete enrollment in its Proellex®-V, or vaginally delivered Proellex® Phase 2 study in the treatment of uterine fibroids at the end of this month. The Company believes it will be able to report study results near year end with the goal to move to Phase 3 early next year.